Formulation And Evaluation Of Chitosan-Based Polyelectrolyte Complex Via Pulmonary Route By Anti-Convulsant Drug Topiramate

Abstract

To far, no medication has been shown to effectively treat epilepsy. As a result, pharmacological therapy concentrates on symptom management by prescribing anti-epileptic drugs for an extended period. Patients with epilepsy may receive treatment in an urgent situation or while using an acute or long-term medicine.Intranasal delivery may involve the systemic pathway, olfactory and trigeminal nerves, and both. Each of these may have a therapeutic influence since the drug can cross the blood brain barrier (BBB) via the systemic pathway. This method lowers the effective dosage relative to other delivery routes, albeit. The term "chitosan" refers to a group of polymers with varying levels of deacetylation and molecular weights that are deacetylated derivatives of the natural polysaccharide chitin. It is made up of N-acetyl-D-glucosamine (acetylated units) and 1,4-linked glucosamine (deacetylated units), with molecular weights ranging from 10 to 1,000 kDa and typical deacetylation levels between 70 and 95 percent.